Healthcare Equipment and Supplies
Company Overview of Ventana Medical Systems, Inc.
Ventana Medical Systems Inc. develops, manufactures, and markets instrument-reagent systems that automate slide staining. Its clinical systems are used in anatomical pathology labs in analyzing human tissue to assist in diagnosing and treating cancer and infectious diseases. Ventana’s drug-discovery systems are used by pharmaceutical and biotech companies to increase the discovery of new drug targets and to evaluate the safety of new compounds. It also markets consumable products, including reagents and other accessories, and serves hospital-based anatomical pathology labs, independent reference labs, government labs, medical research centers, and resellers serving these entities. Ventana Me...
1910 East Innovation Park Drive
Tucson, AZ 85755
Founded in 1985
Key Executives for Ventana Medical Systems, Inc.
Chief Executive Officer and Director
Founder, Chairman Emeritus, Chief Scientific Officer and Chief Medical Officer
Senior Vice President and General Counsel
Vice President of Human Resources and Vice President of Environmental Health & Safety
Compensation as of Fiscal Year 2016.
Ventana Medical Systems, Inc. Key Developments
Loxo Oncology, Ventana Medical Systems Enter Pan-TRK IHC Companion Diagnostic Collaboration
Mar 20 17
Loxo Oncology (LOXO) has entered into a collaboration agreement with Ventana Medical Systems, Inc. to develop and commercialize a pan-TRK immunohistochemistry (IHC) test as a companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib. Larotrectinib, or LOXO-101, is an oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Loxo Oncology and Roche will utilize an investigational assay piloted by Loxo Oncology that will be further developed by Roche using its OptiView DAB detection technology. Initially, the parties will optimize and validate the assay to ensure it is sufficiently robust to withstand clinical and regulatory scrutiny. The parties plan to first globally commercialize an analytical assay and then develop a Class III assay for pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA). FDA approval will be based on analyses of patient samples collected from ongoing larotrectinib clinical trials to support clinical claims referencing larotrectinib. Roche is responsible for developing, obtaining and maintaining regulatory approvals for the companion diagnostic test in the U.S., specified countries in the European Union and other countries that recognize the CE/in vitro diagnostic registration process, as mutually agreed.
Transgenomic, Inc. and Ventana Medical Systems Complete Data Sharing Agreement
Sep 22 16
Transgenomic, Inc. announced that it has signed a data sharing agreement with Ventana Medical Systems, Inc. The agreement allows Ventana to access DNA test results from an existing research agreement between Transgenomic and the University of Melbourne in Australia. As part of this research agreement, the University of Melbourne is conducting additional clinical validation studies of Transgenomic’s Multiplexed ICE COLD-PCR™ (MX-ICP) technology. The collaborative study between Transgenomic and the University of Melbourne is being conducted using DNA isolated from pre-treatment tumor biopsies from patients enrolled in clinical trials. By comparing Next Generation Sequencing (NGS) and MX-ICP, it aims to determine the prevalence and clinical significance of ultra-low frequency mutations that would otherwise go undetected by NGS or Sanger sequencing methodologies. Transgenomic’s Multiplexed ICE COLD-PCR offers major advantages over current sequencing technologies. It delivers at least a 100-fold improvement in sensitivity compared to standard methodologies, allowing detection of both known and previously unknown genetic alterations in any exon of any gene using a single assay. Its ultra-high sensitivity makes it feasible to conduct comprehensive genomic analyses using either tissue or liquid biopsies. MX-ICP is platform agnostic and works on all sequencing platforms found in labs today. It is robust, easy to use and easily implemented, requiring minimal disruption to established sequencing workflows.
Horizon Discovery Group plc and Ventana Medical Systems, Inc. Enter into Co-Development Commercialisation Agreement to Support the Development and Validation of IHC Assays
Sep 1 16
Horizon Discovery Group plc announced that it has entered into a co-development and commercialisation agreement with Ventana Medical Systems, Inc. The Agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standards in cancer tissue diagnostics to support the development and validation of IHC assays. Ventana is a global leader in tissue diagnostics including immunohistochemistry (IHC), providing products used in clinical histology and drug development research laboratories worldwide. To support the development and validation of IHC assays, Ventana has partnered with Horizon as a leading provider of highly characterised Reference Standards. Under the terms of the Agreement, Ventana has the option to commission projects from Horizon, whereupon Horizon will develop the applicable cell lines and the associated derivative Reference Standard materials. Horizon will retain primary responsibility for commercialising the Reference Standards and will serve as the primary distribution channel to end-customers in the growing tissue diagnostics market, thereby providing the Company with additional ongoing revenue streams. Ventana will hold the option to co-distribute any developed Reference Standards.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|